InspireMD Stock Rallies After Vietnam Approves Embolism Prevention Products


27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


InspireMD Inc (NYSE:NSPR) stock rallied Monday on news of regulatory approval for its products.

What Happened

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

InspireMD announced that it received regulatory approval for its CGuard Embolic Prevention System and MGuard Prime in Vietnam. Both of these devices utilize MicroNet technology, and the company has initiated commercialization of products.

Why It's Important

Vietnam has a population of over 100 million and represents an important step in the company's expansion across Asia, Chief Commercial Officer Agustin Gago said in a statement

InspireMD secured a valid import license and product reimbursement from Vietnam's Department of Medical Equipment and Health Works, speeding the products' path to market, the CCO said. 


FREE REPORT: How To Learn Options Trading Fast

In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, ​a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.


What's Next

The Israeli company recently appointed DO GIA as its distributor in Vietnam. DO GIA has an established distribution network across Vietnam that covers both physicians, clinics and hospitals, Gago said.

InspireMD Inc sells the CGuard Embolic Prevention System  and MGuard Prime in a variety of markets across Europe, the Middle East, Asia and Latin America.

Price Action

InspireMD shares were set to close up 9.65 percent Monday at $1.25. 

Related Links:

The Week Ahead In Biotech: PDUFA Dates, Clinical Trials, Merck And Pfizer Earnings On Tap 

FDA Clears New Drug Application For Pluristem's PLX-R18; What's Next? 


27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


Posted In: NewsHealth CareSmall CapGeneralCGuard Embolic Prevention System (EPS)MGuard PrimeRegulatory approval